Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Products under Development by Stage of Development | 8 | 1 |
| Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Products under Development by Therapy Area | 9 | 1 |
| Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Products under Development by Indication | 10 | 1 |
| Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Products under Development by Companies | 13 | 2 |
| Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Products under Development by Universities/Institutes | 15 | 2 |
| Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Therapeutics Assessment | 17 | 7 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 2 |
| Assessment by Route of Administration | 20 | 2 |
| Assessment by Molecule Type | 22 | 2 |
| Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Companies Involved in Therapeutics Development | 24 | 6 |
| Ionis Pharmaceuticals, Inc. | 24 | 1 |
| Neurimmune Holding AG | 25 | 1 |
| ProMIS Neurosciences Inc. | 26 | 1 |
| Thera Neuropharma Inc | 27 | 1 |
| Voyager Therapeutics, Inc. | 28 | 1 |
| Wilson Therapeutics AB | 29 | 1 |
| Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Drug Profiles | 30 | 19 |
| ISIS-SOD1Rx Drug Profile | 30 | 2 |
| Monoclonal Antibodies to Inhibit Superoxide Dismutase 1 for Amyotrophic Lateral Sclerosis Drug Profile | 32 | 2 |
| Monoclonal Antibody 1 to Inhibit SOD1 for Amyotrophic Lateral Sclerosis Drug Profile | 34 | 1 |
| Monoclonal Antibody 2 to Inhibit SOD1 for Amyotrophic Lateral Sclerosis Drug Profile | 35 | 1 |
| Monoclonal Antibody to Inhibit SOD1 for Amyotropic Lateral Sclerosis Drug Profile | 36 | 1 |
| NI-204 Drug Profile | 37 | 1 |
| RNAi Gene Therapy to Inhibit SOD1 for Amyotrophic Lateral Sclerosis Drug Profile | 38 | 1 |
| Small Molecule to Activate SOD-1 for Amyotrophic Lateral Sclerosis and Parkinson's Disease Drug Profile | 39 | 1 |
| Small Molecules to Inhibit Superoxide Dismutase 1 for Amyotrophic Lateral Sclerosis Drug Profile | 40 | 1 |
| TDI-186 Drug Profile | 41 | 1 |
| tetrathiomolybdate Drug Profile | 42 | 1 |
| THN-1 Drug Profile | 43 | 2 |
| VYSOD-101 Drug Profile | 45 | 1 |
| WTX-101 Drug Profile | 46 | 3 |
| Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Dormant Projects | 49 | 1 |
| Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Featured News &Press Releases | 50 | 12 |
| Jun 23, 2016: Wilson Therapeutics Presents Preliminary Clinical Data on Decuprate at the 20th International Congress of Parkinson's Disease and Movement Disorders | 50 | 1 |
| May 30, 2016: Wilson Therapeutics Presents Encouraging Clinical Data On Decuprate At The Congress Of The European Academy Of Neurology | 50 | 1 |
| May 18, 2016: Wilson Therapeutics Announces That the Ongoing Phase II Study Has Been Fully Enrolled | 51 | 1 |
| Apr 29, 2016: Voyager Therapeutics Highlights Program in ALS Disease | 52 | 1 |
| Apr 14, 2016: Wilson Therapeutics presents data on Decuprate (WTX101) from ongoing Phase 2 study at The International Liver Congress 2016 | 52 | 1 |
| Dec 11, 2015: Isis Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Study of ISIS-SOD1 Rx in Patients With ALS | 53 | 1 |
| Apr 16, 2015: Wilson Therapeutics Announces Presentation Of WTX101-201 Phase 2 Study At The EASL 50th International Liver Congress 2015 | 54 | 1 |
| Nov 17, 2014: Wilson Therapeutics Announces Start Of Phase 2 Study To Evaluate The Efficacy And Safety Of WTX101 In Newly Diagnosed Wilson Disease Patients | 54 | 1 |
| Jan 13, 2014: Wilson Therapeutics Announces Successful Filing of U.S. IND to Advance WTX101 Development Program for Wilson Disease | 55 | 1 |
| Apr 03, 2013: MGH And Washington University Researchers Announce Isis Pharma's SOD1 Antisense Drug Demonstrates Safety In Phase I ALS Trial | 55 | 2 |
| Feb 13, 2013: Copper Depletion Therapy May Prevent Risk Of Triple-Negative Breast Cancer, Study Finds | 57 | 2 |
| Apr 28, 2011: RXi Pharmaceuticals and the University of Massachusetts Medical School Announce Massachusetts Life Sciences Center Cooperative Research Grant for RNAi Therapeutics for ALS | 59 | 1 |
| Mar 08, 2010: ISIS Initiates Phase I Clinical Trial Of ISIS-SOD1Rx In Patients With Amyotrophic Lateral Sclerosis | 60 | 1 |
| Dec 13, 2007: Isis Pharmaceuticals Announces ISIS 333611 Granted Orphan Drug Status For Treatment Of ALS | 60 | 1 |
| May 24, 2004: Attenuon Announces Launch Of ATN-224 Phase I Trial In Patients With Solid Tumors | 61 | 1 |
| Appendix | 62 | 2 |
| Methodology | 62 | 1 |
| Coverage | 62 | 1 |
| Secondary Research | 62 | 1 |
| Primary Research | 62 | 1 |
| Expert Panel Validation | 62 | 1 |
| Contact Us | 62 | 1 |
| Disclaimer | 63 | 1 |